跳转至内容
Merck
CN

P2940000

伯氨喹

European Pharmacopoeia (EP) Reference Standard

别名:

磷酸伯安喹, 8-(4-氨基-1-甲基丁氨基)-6-甲氧基喹啉 二磷酸盐, 伯氨喹 二磷酸盐

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C15H21N3O · 2H3PO4
CAS号:
分子量:
455.34
Beilstein:
3812133
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

primaquine

制造商/商品名称

EDQM

mp

205-206 °C (dec.) (lit.)

应用

pharmaceutical (small molecule)

包装形式

neat

储存温度

2-8°C

SMILES字符串

OP(O)(O)=O.OP(O)(O)=O.COc1cc(NC(C)CCCN)c2ncccc2c1

InChI

1S/C15H21N3O.2H3O4P/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14;2*1-5(2,3)4/h4,6,8-11,18H,3,5,7,16H2,1-2H3;2*(H3,1,2,3,4)

InChI key

GJOHLWZHWQUKAU-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Primaquine diphosphate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

象形图

Skull and crossbonesHealth hazard

警示用语:

Danger

危险声明

危险分类

Acute Tox. 3 Oral - Muta. 2 - Repr. 2

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

N P Dhammika Nanayakkara et al.
Antimicrobial agents and chemotherapy, 58(8), 4737-4744 (2014-06-11)
Hematotoxicity in individuals genetically deficient in glucose-6-phosphate dehydrogenase (G6PD) activity is the major limitation of primaquine (PQ), the only antimalarial drug in clinical use for treatment of relapsing Plasmodium vivax malaria. PQ is currently clinically used in its racemic form.
Tamar E Carter et al.
The American journal of tropical medicine and hygiene, 91(2), 412-414 (2014-06-04)
Haiti is one of two remaining malaria-endemic countries in the Caribbean. To decrease malaria transmission in Haiti, primaquine was recently added to the malaria treatment public health policy. One limitation of primaquine is that, at certain doses, primaquine can cause
Improving the radical cure of Plasmodium vivax malaria.
Ric N Price
The American journal of tropical medicine and hygiene, 91(1), 3-4 (2014-04-23)
Interactive medical case. A chilly fever.
Amanda J Redig et al.
The New England journal of medicine, 371(16), e24-e24 (2014-10-16)
Marli S Santana et al.
The American journal of tropical medicine and hygiene, 91(1), 74-76 (2014-05-29)
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is one of the most common human genetic abnormalities, and it has a significant prevalence in the male population (X chromosome linked). The purpose of this study was to estimate the frequency of impaired fasting glucose

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门